INTRODUCTION

Renal impairment (RI) is a common complication in patients with type 2 diabetes mellitus (T2DM). Approximately one in every
five patients with T2DM has an estimated glomerular filtration rate (eGFR) \60 mL/min/ 1.73 m 2 [1] . Presence and severity of RI in patients with T2DM are associated with an increased risk of adverse clinical outcomes, including hospitalization, cardiovascular events, heart failure, end-stage renal disease (ESRD), and premature mortality [2, 3] . Given this elevated risk, there is a strong exigency to intervene in patients with RI. Indeed, studies suggest that a greater reduction in the absolute risks in this population may be achieved with intensive treatment of blood pressure or lipid levels, and fewer patients may need treatment to prevent one event, compared with individuals with normal renal function who required treatment [4, 5] . However, intensive control of blood glucose levels in patients with T2DM and RI is challenging and often regarded as problematic, which also compromises glycemic control leading to therapeutic inertia. A robust association exists between glycated hemoglobin (HbA1c) and clinical outcomes in patients with RI [2] ; however, in patients with T2DM, presence of RI is associated with an increase in the risk of adverse events (AEs) such as hypoglycemia [6] , gastrointestinal symptoms [7] , fluid retention [8] , and bone fracture [9] . In addition, RI directly or indirectly affects the pharmacokinetics and pharmacodynamics of several glucose-lowering agents and demands dose adjustment while prescribing these agents in patients with RI [10] . Some glucose-lowering agents such as sodium glucose cotransporter-2 (SGLT-2) inhibitors are less effective in patients with RI [9] . Moreover, a high pill burden and the challenges of treatment compliance may also make treatment intensification even more difficult in patients with RI [11] . Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the management of T2DM and have confirmed efficacy and safety, without increasing the risk of hypoglycemia and weight gain in patients with normal renal function [12] .
In addition, DPP-4 inhibition has the potential to address several impediments associated with intensification of glycemic control in patients with RI [13] . However, limited data on comparative efficacy and safety of inhibitors are available, especially in patients with RI. Consequently in this paper, we report the findings from a systematic literature review of the efficacy and safety of DPP-4 inhibitors in patients with T2DM and RI.
METHODS
Search
We conducted a search of all English language studies on DPP-4 inhibitors in patients with Table S1 in the supplementary material).
Outcomes
The outcomes included changes in HbA1c and FPG at weeks 12 and 52. Overall safety, incidence of hypoglycemic events (HEs) and renal function were also reported.
Additional Analyses
In the vildagliptin studies [14, 15] 
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RESULTS
Identified Studies
Overall, we identified 4542 studies during the initial search ( Fig. 1) , among which 51 studies were shortlisted following deletion of duplicates and screening based on titles and abstracts. Of these 51 studies, 7 studies met the inclusion criteria during the screening based on full text: 5 were placebo-controlled trials (one each on vildagliptin [14] , sitagliptin [16] , and saxagliptin [17] , and two on linagliptin [19, 20] ), and the remaining two were 52-week extension studies of vildagliptin [15] and saxagliptin [18] . The study designs of the studies included in this review are summarized in the supplementary material (Table S2 ). There were no full-text publications available for gemigliptin, alogliptin, or teneligliptin that met the inclusion criteria, at the time when the search was conducted.
Patient Demographics and Baseline
Characteristics
Demographics and baseline characteristics of patients were broadly similar across treatment groups and within each study, with mean age ranging from 64 to 70 years (Table 1) . Over 50% patients across the study groups were men, except in the saxagliptin study, which had more women (approximately 62% only approximately 11% received insulin in the placebo-controlled phase of the trial. In the vildagliptin study, almost all patients were on anti-hypertensive agents that block the renin-angiotensin-aldosterone system (RAAS). The following criteria were applied for screening of title/ abstract but did not lead to any exclusions: outcomes, trial length and comparator arms; 2 the following criteria were applied for screening of full text but did not lead to any exclusions: study type, treatment, outcomes, trial length B12 weeks, and sample size B50; 3 two studies are extensions of other studies included in the analysis after screening of full text [15, 18] . Relevant studies that only report outcomes for renally impaired patients with type 2 diabetes mellitus in the full text may have been excluded if the title or abstract of the study does not mention this subpopulation [16] Vildagliptin [14] Overall RI Similarly, in the sitagliptin study, the most frequent concomitant medication was a RAAS inhibitor ([70%) and in the linagliptin study, [90% patients were on anti-hypertensive agent.
In the saxagliptin study, use of any concomitant medications other than glucose-lowering agents was not reported.
In the sitagliptin study, open-label rescue therapy (insulin up-titration or initiation of sulfonylurea or insulin) was available throughout the study if pre-specified glycemic control criteria were not met [16] . In the vildagliptin study, rescue medication, as insulin addition or intensification was permitted after 4 weeks if pre-specified glycemic control criteria were not met [14, 15] . In the saxagliptin study, patients were discontinued from the study if pre-specified glycemic control criteria were not met [17, 18] .
In the linagliptin study, stable doses of background therapy were maintained in the first 12 weeks of the study, unless dose adjustments were necessary due to safety reasons, and in the following 40-week treatment period, background therapy could be adjusted according to glucose parameters; rescue therapy (insulin addition) was allowed based on failure to meet pre-specified glycemic response criteria at any time point during the study [19] .
Reduction in HbA1c
In each long-term study, the HbA1c-lowering effect from a given baseline was similar at weeks 12 and 52 in the overall population (both moderate and severe RI, Fig. 2a ), implying sustainable effects in this setting. In the 12-week sitagliptin study, a placebo-adjusted mean HbA1c reduction of 0.4% (baseline, 7.6%; 95% confidence interval [CI], -0.7 to -0.1) was observed in the overall population [16] . The Table 1 continued Parameter Linagliptin [19, 20] Saxagliptin [17] Sitagliptin a [16] Vildagliptin [14] Overall RI In patients with moderate RI, the placebo-adjusted mean reduction in HbA1c in vildagliptin-treated patients at week 12 was 0.63% and at week 52 was 0.4%, which was statistically significant (P = 0.005; Fig. 2b ) [14, 15] . Similarly, saxagliptin-treated patients showed numerically higher placebo-adjusted mean reductions in HbA1c at weeks 12 (0.59%) and 52 (1.13%) [17, 18] . HbA1c data for sitagliptin-and linagliptin-treated patients with moderate RI are not available in their individual publications [16, 19, 20] .
In patients with severe RI treated with vildagliptin, the placebo-adjusted mean reduction in HbA1c of 0.5% at week 12 and 0.7% (P\0.0001) at week 52 was significant (Fig. 2c) ; P\0.05).
Reduction in FPG
The mean reductions in FPG from baseline at weeks 12 and 52 in the overall population of each study are depicted in Fig. 3a ; further stratifications by moderate RI (Fig. 3b ) and severe RI (Fig. 3c) subgroups are also shown. In the 12-week sitagliptin study, the difference in FPG between sitagliptin-and placebo-treated patients was -1.3 mmol/L (95% CI, -2.2 to -0.3) [16] .
Safety and Tolerability
Overall, the incidences of AEs were similar between the active treatment and placebo groups across all studies ( Table 2 ). The number of patients reporting any AE, drug-related AEs, serious AEs, and AEs leading to treatment discontinuation in the treatment groups were broadly similar to that of their corresponding placebo groups, and AEs were mild to moderate in severity [14] [15] [16] [17] [18] [19] [20] .
In every study, the most frequently reported AE was hypoglycemia (Table 3) . For sitagliptin, during the 12-week, placebo-only controlled phase of the trial, the incidence of hypoglycemia was similar between both Not included long-term data for sitagliptin [16] and linagliptin [20] studies because of its combined placebo and active-controlled phase. All hypoglycemic events observed in the study were mild or non-severe in nature. In the vildagliptin study, hypoglycemia was defined as symptom suggestive of low blood glucose confirmed by SMBG measurement \3.1 mmol/L plasma glucose equivalent. Severe hypoglycemia was defined as any episode requiring assistance from another person whether or not a confirmatory SMBG measure was available [14, 15] . In the saxagliptin study, hypoglycemia was defined as any event consistent with signs or symptoms of hypoglycemia with or without documented glucose levels. Confirmed hypoglycemia was defined by a finger-stick glucose value B2.8 mmol/L with associated symptoms [17, 18] . In the linagliptin study, hypoglycemia was defined as symptoms suggestive of low blood glucose confirmed by SMBG measurement\3.9 mmol/L plasma glucose equivalent. Severe hypoglycemia was defined as any event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions [19, 20] b 12-week data unavailable for vildagliptin groups (sitagliptin, 4.6% vs. placebo, 3.8%) [16] .
In the vildagliptin study, the incidences of hypoglycemia in the overall population at weeks 24 and 52 were comparable with placebo [14, 15] . In patients with moderate RI, the incidence of HEs was numerically higher in patients who received active treatment versus those who received placebo at weeks 24 and 52. The incidence of severe hypoglycemia was similar between the treatments (vildagliptin, 1.2% vs. placebo, 1.6%) at week 24 [14] . In the severe RI group, the incidences of hypoglycemia were similar with vildagliptin and placebo at both weeks 24 and 52 [14, 15] . However, the incidence of severe hypoglycemia was lower with vildagliptin than placebo at week 52 in patients with both moderate and severe RI [15] .
In the saxagliptin study, the incidences of hypoglycemia were similar in both active and placebo groups at weeks 12 and 52 in the overall population and in patients with moderate RI and ESRD [17, 18] . However, in patients with severe RI, the incidence of hypoglycemia in the saxagliptin-treated patients was almost double that in the placebo-treated patients at weeks 12 (27.8% vs. 13.0%) and 52 (33.3% vs. 17.4%) [17, 18] . In the 12-week placebo-controlled phase, the incidence of hypoglycemia was comparable between linagliptin and placebo in the overall population [20] . In another study, the incidence of hypoglycemia was higher in linagliptin-treated patients with severe RI than in placebo-treated patients at weeks 12 and 52;
this was attributed to the higher incidence of asymptomatic hypoglycemia with linagliptin [19] . However, the incidence of severe hypoglycemia was low and similar between both groups: 4.4% with linagliptin and 4.6%
with placebo [19] .
Renal Findings
In the vildagliptin study, there was a slight but similar decline in eGFR over 52 weeks in both vildagliptin and placebo groups (moderate RI, -1.62 vs. -1.80 mL/min; severe RI, -1.98 vs.
-2.44 mL/min, respectively). The mean serum potassium levels were more or less unchanged over the course of the year. The incidence of hyperkalemia was comparable between vildagliptin-and placebo-treated patients in both moderate (3.3% vs. 3.4%) and severe RI (10.6% vs. 6.3%) groups. This incidence was slightly higher in severe RI group than in moderate RI group [15] . In the saxagliptin study, patients with moderate or severe RI reported a slight decline in eGFR over with placebo at different time points [14] [15] [16] [17] [18] [19] [20] . This is comparable to the reductions observed in placebo-controlled trials in patients with normal renal function, particularly when DPP-4 inhibitors were added to pre-existing [21] and often long-term insulin therapy (the most common background therapy in studies included in this analysis). The findings reported in the present review were in line with a previously reported systematic review and meta-analysis of 10 pooled studies conducted in patients with moderate and severe RI [22] .
Notably, a modest (0.1-0.2%) but greater additional reduction in HbA1c was observed in patients with severe RI (eGFR, \30 mL/min/ 1.73 m 2 ) than in those with moderate RI (eGFR, 30-60 mL/min/1.73 m 2 ; P\0.05). It is possible to speculate that patients with severe RI may show a greater increase in glucagon-like peptide-1 (GLP-1) as its half-life is further prolonged by reduced renal clearance [23] . In addition, the reduced half-life of erythrocytes in patients with severe RI may have underestimated glycemic control in such patients than in those with better renal function [24] . As the effects of DPP-4 inhibition (and incretin effect) on glycemia are proportionally greater in individuals with higher baseline glucose levels [25] , a greater reduction in HbA1c may be anticipated in patients with severe RI who are likely to have had higher glucose levels despite having comparable baseline HbA1c levels to those with moderate RI.
Hypoglycemia, a frequent complication of diabetes management, affects approximately 25% of patients with T2DM at least once a year [26] . It is also often an important barrier to optimized glycemic control [27] . RI is associated with an increased incidence and severity of HEs [28] . Indeed, in all studies included in the present analysis, 1-4% of patients with RI experienced a severe HE (requiring assistance). This proportion is 5-to 10-times higher than that reported in patients with normal renal function [29] , even without adjusting for the appropriate dose of insulin or insulin secretagogues in this setting. However, the addition of DPP-4 inhibitors in this setting achieved improved glycemic control without any significant increase in HEs in any individual study compared with placebo. Moreover, it is likely that in clinical settings, pre-emptive down-titration of insulin/sulfonylurea dosage following improvement in glycemic control induced by DPP-4 inhibition should result in even lower rates of hypoglycemia in patients receiving DPP-4 inhibitors. However, in blinded placebo-controlled trials, any down-titration is generally limited and would not occur until the patient experiences a HE or records lower glucose levels [14] [15] [16] [17] [18] [19] [20] .
Moreover, T2DM management in patients with RI is associated with higher health care costs and reduced health-related quality of life [1, 30] , which is partly mediated by the presence and severity of co-morbid diseases and multi-factorial interventions necessitated by their presence [30] . In addition, the frequency inhibitors may have renal benefits beyond glucose lowering [35] and have also reported modest reductions in albuminuria [36, 37] .
However, it is unclear whether this is a valid marker of renal protection achieved by these agents. In the SAVOR TIMI-53 study (ClinicalTrials.gov identifier: NCT01107886), despite reduction in albuminuria, there was no difference in ESRD or progressive renal decline between patients receiving saxagliptin and those receiving placebo [37] . At present, it can be concluded that there is no evidence of any adverse effect on renal function following the use of DPP-4 inhibitors (i.e., renal safety) in patients with T2DM and RI [15, 19] . Longer studies with a focus on renal safety remain to be completed to establish any renoprotective effects in addition to glycemic control.
However, fundamentally, for the use of DPP-4 inhibitors in patients with RI, the ability to safely lower glucose levels is the primary attribute and indication.
CONCLUSIONS
In summary, for patients with T2DM and RI, diabetes management is complex, multi-dimensional and potentially expensive. 
